Faculty Bibliography

The findings suggest that at least 10 million Americans and their doctors may want to add the drug, ramipril, to standard heart therapies and that it could save tens of thousands of lives each year at a cost of about 85 cents a day, the study's chief author, Dr. Salim Yusuf of McMaster University in Hamilton, Ontario, Canada, said yesterday in an interview. The study was conducted among individuals with heart or blood vessel disease but without heart failure, Dr. Yusuf said in reporting the findings yesterday. Participants in the study also had at least one risk factor for heart disease or strokes, like high blood pressure, elevated cholesterol levels or cigarette smoking. For every 1,000 individuals who took ramipril once a day for four years, the study found that 70 would avoid a total of 150 serious problems, including heart attacks, strokes, the need for bypass surgery and death. Ramipril's benefits were ''at least as large'' as other drugs like aspirin, beta-blockers and those that lower lipids, Dr. Yusuf's team said, adding that in the study ramipril had been taken in conjunction with those other drugs, not as a substitute for them

A drug that has been marketed for eight years to combat high blood pressure turns out to substantially lower the risk of heart attack, stroke, bypass surgery and diabetes and its complications in those who have heart disease, scientists reported Wednesday. The findings suggest that at least 10 million Americans and their doctors may want to add the drug ramipril to standard heart therapies and that it could save tens of thousands of lives each year at a cost of about 85 cents a day, the study's chief author, Dr. Salim Yusuf of McMaster University in Hamilton, Ontario, said in an interview. The study was conducted among individuals with heart or blood- vessel disease but without heart failure, Yusuf said in reporting the findings Wednesday at the AHA meeting. Participants also had at least one risk factor for heart disease or strokes, like high blood pressure, elevated cholesterol levels or cigarette smoking

A drug that has been marketed for eight years to combat high blood pressure turns out to substantially lower the risk of heart attack, stroke, bypass surgery, and diabetes and its complications in those who have heart disease, scientists reported yesterday. The findings suggest that at least 10 million Americans and their doctors may want to add the drug, ramipril, to standard heart therapies and that it could save tens of thousands of lives each year at a cost of about 85 cents a day, the study's chief author, Dr. Salim Yusuf of McMaster University in Hamilton, Ontario, said in an interview

An ACE inhibitor is found to lower the risk of heart attack, stroke and the complications of diabetes. A drug that has been marketed for eight years to combat high blood pressure turns out to substantially lower the risk of heart attack, stroke and diabetes and its complications in those who have heart disease, scientists reported Wednesday. The findings suggest that at least 10 million Americans and their doctors may want to add the drug, ramipril, to standard heart therapies and that it could save tens of thousands of lives each year at a cost of about 85 cents a day, said the study's chief author, Dr. Salim Yusuf of McMaster University in Hamilton, Ontario, in an interview

Summary: The author of a study says adding ramipril to current therapies could save tens of thousands of lives a year A drug that has been marketed for eight years to combat high blood pressure turns out to produce a substantial reduction in the risk of heart attack, stroke and bypass surgery and in diabetes and its complications in those who have heart disease, scientists reported Wednesday. The findings suggest that at least 10 million Americans and their doctors may want to add the drug, ramipril, to standard heart therapies and that it could save tens of thousands of lives each year at a cost of about 85 cents a day, said the study's chief author, Dr. Salim Yusuf of McMaster University in Hamilton, Ontario

A drug that has been marketed for eight years to combat high blood pressureturns out to substantially lower the risk of heart attack, stroke, bypasssurgery, and diabetes and its complications in those who have heart disease,scientists reported yesterday. The findings suggest that at least 10 million Americans and their doctorsmay want to add the drug, ramipril, to standard heart therapies and that itcould save tens of thousands of lives each year at a cost of about 85 cents aday, said the study's chief author, Dr. Salim Yusuf of McMaster University inHamilton, Ontario, in an interview. The study was conducted among individuals with heart or blood vesseldisease but without heart failure, Yusuf said in reporting the findingsyesterday at the AHA meeting in Atlanta. Participants also had at least onerisk factor for heart disease or strokes, such as high blood pressure,elevated cholesterol levels or cigarette smoking

Each year millions of people in third world countries develop similar symptoms from malaria, a parasitic infection carried by the Anopheles mosquito, and many die. Far fewer cases occur in the United States: Mr. [Sean] Cavanaugh's is one of about a thousand. Like almost all patients here, he survived. Either way, the case underscores the importance of diagnosing once-common infections like malaria that are now rare in the United States. In 1914, malaria infected at least 600,000 Americans. Now all but about 10 cases reported here each year are among Americans who contracted malaria overseas or among people who have moved to the United States from areas where the infection remains. The infection's control in the United States came from wiping out the parasite, not by eliminating the Anopheles mosquito. It remains. That afternoon, Dr. [James] Salik referred Mr. Cavanaugh to Dr. David A. Silverman, an expert in infectious diseases at New York University. Both doctors would ask a similar question: Where have you traveled recently? Honduras in the spring, Mr. Cavanaugh told them

The infection can progress with devastating rapidity even under the best of medical care; what starts as a mild flulike infection can kill an otherwise healthy person in hours. A single case of meningococcal meningitis can prompt emergency public health drills to identify the scores of people with whom the victim came in contact before falling ill, so that each can be given immediate antibiotic therapy. The accompanying media attention intensifies the air of panic. The panel, which advises the Centers for Disease Control and Prevention on immunization practices, called on universities and health professionals last month to tell college freshmen and their parents about the availability of a well-established vaccine that is safe and effective against most subtypes of the bacteria affecting college-age Americans. (The vaccine is not recommended for general population because of the low incidence of infection, and it is not effective against the subtype of bacteria that causes most cases among infants and occasional cases in other age groups.) Scientists do not know why. The centers recently conducted an extensive survey, said Dr. Nancy E. Rosenstein, an expert there in the epidemiology of meningococcal infections, but could not come up with an answer. ''It was not smoking, drinking, attending bars or anything else we asked about,'' Dr. Rosenstein said. ''It may have something to do with the difference in the behavior of freshmen living in dormitories compared to other groups of students, and despite our study we were not able to identify what that was.''

In a rare and embarrassing reversal, a Federal health advisory panel yesterday withdrew its recommendation that all infants be immunized against the virus that causes a severe form of diarrhea after the vaccine was linked to a painful and potentially fatal bowel obstruction. The action comes a year after the Government licensed the rotavirus vaccine, and three months after it abruptly suspended its use because of reports that some babies who took it were coming down with the bowel condition. A week ago the manufacturer, American Home Products of Madison, N.J., withdrew the vaccine from the market. Despite the suspension in July, the advisory panel's formal position until yesterday had been that all infants in the United States should receive three doses of the vaccine, at 2, 4 and 6 months of age. Rotashield is the world's first and only licensed vaccine against rotavirus, though it is not being used in other countries

She is Dr. Catherine D. DeAngelis, 59, who worked for four years as a nurse before going to college and then medical school. Dr. DeAngelis will leave her job as a vice dean at Johns Hopkins University School of Medicine in Baltimore and will step down as editor of the A.M.A.'s journal Archives of Pediatrics and Adolescent Medicine. Dr. DeAngelis's appointment as the 15th editor of the Journal of the American Medical Association comes as many scientific journals are under pressure to increase income for the professional societies and companies that own them. Dr. DeAngelis's predecessor, Dr. George D. Lundberg, was dismissed in January, accused of publishing a paper on whether college students think oral sex is ''having sex'' to influence President Clinton's impeachment trial. The dismissal fueled a controversy over the journal's editorial independence